IOVAHealthcare · BiotechnologyThe 9 Wall Street analysts covering Iovance Biotherapeutics, Inc. hold a median 12-month price target of $9 — +28.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 15 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Iovance Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (94): The business earns solid, repeatable profits on what it owns.
Volatility (33): The share price moves around a lot.
Size (31): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on IOVA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +28.9% from it.
Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | Barclays | Maintains | Overweight | $11 → $13 |
| 7 Aug 2026 | Citizens | Maintains | Market Outperform | $5.00 → $8.00 |
| 8 May 2026 | Chardan Capital | Maintains | Buy | — |
| 7 May 2026 | Chardan Capital | Maintains | Buy | $16 → $14 |
| 10 Apr 2026 | Chardan Capital | Maintains | Buy | — |
| 5 Mar 2026 | UBS | Maintains | Neutral | — |
| 3 Mar 2026 | Citizens | Upgrade | Market Outperform | — |
| 25 Feb 2026 | Barclays | Maintains | Overweight | — |
| 25 Feb 2026 | Citizens | Upgrade | Market Outperform | — |
| 17 Dec 2025 | Barclays | Maintains | Overweight | — |
| 24 Nov 2025 | Barclays | Maintains | Overweight | — |
| 6 Nov 2025 | Chardan Capital | Maintains | Buy | — |
| 29 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 19 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 8 Aug 2025 | Wells Fargo | Maintains | Overweight | — |
| 23 July 2025 | Chardan Capital | Maintains | Buy | — |
| 16 May 2025 | UBS | Downgrade | Neutral | — |
| 12 May 2025 | Barclays | Maintains | Overweight | — |
| 12 May 2025 | Goldman Sachs | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IOVA appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 91% of US stocks
Cheaper than 15% of US stocks
Cheaper than 26% of US stocks
Cheaper than 85% of US stocks
Higher than 90% of US stocks
Higher than 79% of US stocks
Higher than 69% of US stocks
Higher than 16% of US stocks
Higher than 6% of US stocks
Higher than 24% of US stocks
Higher than 19% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Iovance Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Iovance Biotherapeutics reported Q2 results showing a 66% rise in revenue, driven by strong demand for Amtagvi, and reduced its losses by nearly 60%.
Why it matters — The results demonstrate accelerating adoption of Amtagvi and meaningful progress toward profitability, two key metrics for Iovance investors.
Iovance reported second-quarter results that beat estimates, with Amtagvi sales exceeding forecasts and boosting revenues. The company's stock rose 43%, and management said it is reviewing full-year guidance in light of the results.
Why it matters — The strong Amtagvi uptake and revenue beat prompted a review of full-year guidance, signaling momentum behind Iovance's key commercial product.
Zacks Investment Research reports that the mean of analysts' price targets for Iovance Biotherapeutics points to a roughly 28% upside in the stock. The article notes that while this price-target metric has not proven highly effective, strong agreement among analysts in raising earnings estimates indicates potential upside.
Why it matters — IOVA watchers would care because analyst price targets and earnings estimate revisions can signal the market's expected direction for the stock.
Iovance Biotherapeutics reported record second-quarter revenue and gross margin, driven by demand for its Amtagvi tumor-infiltrating lymphocyte (TIL) therapy. The company also expanded its treatment-center network and advanced clinical programs in lung cancer, sarcoma, and gynecologic cancers.
Why it matters — A IOVA watcher would care because the record revenue and margin signal strong commercial traction for Amtagvi while the company broadens its treatment network and pipeline.
Iovance Biotherapeutics reported strong Q2 results, with product revenues of $99M (10% above guidance), a 56% gross margin, and a net loss of $(47.3M) that beat consensus. The company has upcoming data presentations for frontline melanoma and NSCLC at ESMO, with a BLA submission for NSCLC planned next year.
Why it matters — A IOVA watcher would care because the better-than-expected Q2 results and the critical melanoma and NSCLC data due in September represent key near-term catalysts for the company's pipeline.
The 9 Wall Street analysts covering Iovance Biotherapeutics, Inc. have a median 12-month price target of $9, with estimates ranging from $4 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering Iovance Biotherapeutics, Inc., 7 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Iovance Biotherapeutics, Inc. 90 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Iovance Biotherapeutics, Inc. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (94 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +28.9% from the last close, and Ticker Nerd's factor model ranks Iovance Biotherapeutics, Inc. 90 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Iovance Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IOVA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $14 over the next 12 months.
Iovance Biotherapeutics, Inc. returned +184.9% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Iovance Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing cell therapies for cancer.
The most recent item we track (The Motley Fool, 10 Aug 2026): "Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher?". Iovance Biotherapeutics reported Q2 results showing a 66% rise in revenue, driven by strong demand for Amtagvi, and reduced its losses by nearly 60%.
Iovance Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing cell therapies for cancer. The company specializes in tumor-infiltrating lymphocyte, or TIL, therapies designed to use a patient’s own immune cells to recognize and attack solid tumors. Its product portfolio includes Amtagvi, an individualized T-cell therapy for advanced melanoma, and Proleukin, an interleukin-2 therapy used in oncology care. Iovance Biotherapeutics also maintains a broader clinical pipeline spanning multiple solid tumor indications, including cervical cancer, head and neck cancer, and other advanced cancers. Headquartered in San Carlos, California, Iovance Biotherapeutics plays a specialized role in the immunotherapy market by advancing personalized treatment approaches for patients with difficult-to-treat cancers.
CEO Dr. Frederick G. Vogt Esq., J.D., Ph.D. · 975 employees · United States · https://www.iovance.com